

Resource Summary Report

Generated by [nidm-terms](#) on Aug 21, 2026

Anti-CD8 antibody [SP239]

RRID:AB_2756374

Type: Antibody

Proper Citation

Abcam Cat# ab178089, RRID:AB_2756374

Antibody Information

URL: http://antibodyregistry.org/AB_2756374

Proper Citation: Abcam Cat# ab178089, RRID:AB_2756374

Target Antigen: CD8

Host Organism: rabbit

Clonality: monoclonal

Comments: Applications: IHC-P

Antibody Name: Anti-CD8 antibody [SP239]

Description: This monoclonal targets CD8

Target Organism: human

Clone ID: SP239

Antibody ID: AB_2756374

Vendor: Abcam

Catalog Number: ab178089

Alternative Catalog Numbers: M5390

Record Creation Time: 20250819T220007+0000

Record Last Update: 20250820T004730+0000

Ratings and Alerts

No rating or validation information has been found for Anti-CD8 antibody [SP239].

No alerts have been found for Anti-CD8 antibody [SP239].

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 14 mentions in open access literature.

Listed below are recent publications. The full list is available at [nidm-terms](#) .

Melero I, et al. (2026) Cergutuzumab Amunaleukin in Combination with Atezolizumab in Patients with Carcinoembryonic Antigen-Positive Advanced/Metastatic Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research, 32(3), 528.

Lee LH, et al. (2025) Defining Non-small Cell Lung Cancer Tumor Microenvironment Changes at Primary and Acquired Immune Checkpoint Inhibitor Resistance Using Clinical and Real-World Data. Cancer research communications, 5(6), 1049.

Solomon BJ, et al. (2025) The Impact of the Tumor Microenvironment on the Effect of IL-1 ? Blockade in NSCLC: Biomarker Analyses from CANOPY-1 and CANOPY-N Trials. Cancer research communications, 5(4), 632.

Dalangood S, et al. (2025) Cancer-associated adipocytes mediate CD8+T cell dysfunction via FGF21-driven lipolysis. Cell reports, 44(11), 116526.

Xu M, et al. (2025) Effects of anlotinib combined with camrelizumab and chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma on tumor immune microenvironment. Journal of gastrointestinal oncology, 16(4), 1366.

Dai D, et al. (2024) Chemoradiotherapy-induced ACKR2+ tumor cells drive CD8+ T cell senescence and cervical cancer recurrence. Cell reports. Medicine, 5(5), 101550.

Zhao J, et al. (2024) Decision model for durable clinical benefit from front- or late-line immunotherapy alone or with chemotherapy in non-small cell lung cancer. Med (New York, N.Y.), 5(8), 981.

Gong C, et al. (2024) Preclinical study and phase 2 trial of neoadjuvant pyrotinib combined with chemotherapy in luminal/HER2-low breast cancer: PILHLE-001 study. Cell reports. Medicine, 5(11), 101807.

Aggarwal C, et al. (2023) Safety and Efficacy of MEDI0457 plus Durvalumab in Patients with Human Papillomavirus-Associated Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 29(3), 560.

Gong C, et al. (2023) Exploration of the immunogenetic landscape of hyperprogressive disease after combined immunotherapy in cancer patients. *iScience*, 26(6), 106720.

Li J, et al. (2023) Remodeling of the immune and stromal cell compartment by PD-1 blockade in mismatch repair-deficient colorectal cancer. *Cancer cell*, 41(6), 1152.

Wang J, et al. (2022) Spatial Metabolomics Identifies Distinct Tumor-Specific Subtypes in Gastric Cancer Patients. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 28(13), 2865.

Zheng KF, et al. (2021) PD-L1 expression and immune cells infiltration in primary tracheobronchial neoplasm. *Translational lung cancer research*, 10(12), 4617.

Halbrook CJ, et al. (2019) Macrophage-Released Pyrimidines Inhibit Gemcitabine Therapy in Pancreatic Cancer. *Cell metabolism*, 29(6), 1390.